- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07621471
IL-15 Enhanced NK Cell Therapy for Solid Tumors
A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed/Metastatic Solid Tumors
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Chongqing, Kina
- Rekruttering
- Xinqiao Hospital
-
Ta kontakt med:
- Xinqiao Hospital
- Telefonnummer: +86-23-68763468
- E-post: jiaqingzhu0801@outlook.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18-70 years;
- ECOG 0-1;
- histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);
- failed prior standard therapy;
- >=1 measurable lesion per RECIST 1.1;
- adequate bone marrow, liver, kidney, and coagulation function;
- recovered from prior treatment toxicities;
- signed informed consent.
Exclusion Criteria:
- Pregnancy/lactation;
- other malignancy within 5 years (except cured localized tumors);
- active autoimmune disease or immunodeficiency;
- uncontrolled cardiovascular disease or infection;
- active TB;
- positive HBsAg/HBcAb or HCV antibody (unless viral load undetectable);
- positive syphilis antibody;
- major surgery or vaccination within 28 days;
- prior cell therapy;
- severe allergy to study drugs;
- investigator judged unsuitable.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: IL-15 Enhanced Engineered NK Cells
Single arm. Patients receive IL-15 enhanced engineered NK cells after lymphodepletion chemotherapy. |
Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details. Genetically engineered NK cells expressing IL-15 |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of Dose-Limiting Toxicity (DLT)
Tidsramme: Within 28 days after first infusion
|
Within 28 days after first infusion
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Every 4 weeks for the first 6 months, then every 12 weeks through 24 months
|
Every 4 weeks for the first 6 months, then every 12 weeks through 24 months
|
|
Duration of Response (DOR)
Tidsramme: From date of first documented response until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
From date of first documented response until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Progression-Free Survival (PFS)
Tidsramme: From date of enrollment until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
From date of enrollment until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Overall Survival (OS)
Tidsramme: From date of enrollment until date of death from any cause, assessed up to 24 months
|
From date of enrollment until date of death from any cause, assessed up to 24 months
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Expansion and persistence of IL-15 enhanced engineered NK cells and cytokine levels
Tidsramme: Baseline (Day 0), Day 1, Day 3, Day 7, Day 14, Day 28, then every 4 weeks through 6 months, then every 12 weeks through 12 months
|
Baseline (Day 0), Day 1, Day 3, Day 7, Day 14, Day 28, then every 4 weeks through 6 months, then every 12 weeks through 12 months
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026-08-02
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .